Imported Drugs Now Need 12 Months of Shelf Life Under New Rule
India now requires imported medicines to have at least 12 months of shelf life left on arrival, replacing the 60% rule; biologics and radiopharmaceuticals keep a 60% test.
India now requires imported medicines to have at least 12 months of shelf life left on arrival, replacing the 60% rule; biologics and radiopharmaceuticals keep a 60% test.
The US FDA has approved Sun Pharma’s sBLA for ILUMYA (tildrakizumab-asmn) in adults with active psoriatic arthritis, backed by the Phase 3 INSPIRE-1 and INSPIRE-2 studies. The provider-administered IL-23 inhibitor, approved for plaque psoriasis since 2018, now addresses a US PsA population of about 2.4 million.
SCHOTT Poonawalla is now SCHOTT Pharma India, effective 28 October 2026. Ownership and operations are unchanged, but the rebrand ties India’s only glass prefillable syringe maker, which produces 3 billion+ containers a year, closer to its German parent as it adds syringe and cartridge capacity for biologics, biosimilars and GLP-1s.
Swiss B2B pharma company Adalvo has acquired Pune-based Enzene’s romiplostim biosimilar programme referencing Amgen’s Nplate, while Enzene stays on as development and manufacturing partner and sharpens its focus on biologics CDMO services.
Syngene International’s Q2 FY27 revenue rose 13% quarter-on-quarter to ₹833 crore and operating EBITDA margin improved six points to 18%, helped by CDMO traction, while the company signed its first manufacturing agreement for its Bayview biologics facility in the US.
India’s biopharma ecosystem is entering a significant phase of transformation, driven by policy support, increased startup funding, growing innovation and […]